Venus Remedies marks another leap in its international expansion

Venus Remedies continues to strengthen its global footprint with new marketing authorizations and product registrations across key international markets across Latin America, the Middle East, Europe, Central Asia, and Africa.

At Venus Remedies, every new market represents an opportunity to make quality medicines more accessible to patients worldwide. Continuing this journey, the company has achieved another series of regulatory milestones, securing marketing authorizations and product registrations across Peru, Kuwait, Argentina, Slovenia, Kazakhstan, and South Africa.

These achievements reflect Venus Remedies' growing international presence and its continued focus on expanding access to oncology and anti-infective therapies.

Expanding Global Regulatory Footprint

Venus Remedies has received new marketing authorizations for several important pharmaceutical products, further strengthening its presence across diverse therapeutic segments.

In Peru, the company secured marketing authorization for Fulvestrant 250 mg/5 ml, an oncology treatment used in certain types of breast cancer.

In Kuwait, approvals were received for Methotrexate 50 mg/2 ml, used in oncology and certain autoimmune conditions, and Ceftazidime & Avibactam 2.5 g, an antibiotic combination used to treat serious bacterial infections.

Strengthening its anti-infective portfolio in Argentina, Venus Remedies received marketing authorizations for Meropenem 500 mg and 1 g, both used in the management of serious bacterial infections.

Meanwhile, Slovenia granted marketing authorization for Cisplatin 100 mg/100 ml, adding another important oncology product to the company's international portfolio.

A New Beginning in Kazakhstan

Marking a significant step in its Central Asian expansion, Venus Remedies secured its first product registrations in Kazakhstan.

The registrations include Fluorouracil 250 mg, 500 mg, and 1000 mg, used in cancer treatment, along with Vancomycin 1 g, an antibiotic used against serious bacterial infections.

This milestone establishes an important regulatory foundation for the company's future growth in Kazakhstan, creating opportunities to build its presence in the market while expanding its portfolio of oncology and anti-infective medicines. 

Strengthening Our Presence in South Africa

Further extending its reach, we also achieved another regulatory milestone in South Africa with approvals for our flagship products: Elores 1.5 g and Elores 3.0 g.

These approvals add momentum to the company’s mission to “Lead global science and discovery in AMR solutions for critical care when existing treatments fail.”

Taking Our Global Ambition Forward

From securing new registrations in previously untapped markets to expanding established product portfolios, these milestones reflect the collective efforts driving Venus Remedies' international growth. 

The journey continues, with more markets to reach, partnerships to build, and possibilities to explore.